Investor Relations Home
Due to an error by our third-party webcasting provider, the live webcast on August 9 was disconnected for approximately three minutes during the Q&A segment. However, the complete webcast is available for replay on demand.
Here you will find financial reports and shareholder information about Omeros Corporation, including recent news, current and historical share price, and electronic copies of our SEC filings.
|Recent Press Releases||More >>|
|Date||Title|| || |
|08/12/16||Omeros to Present at the 2016 Wedbush PacGrow Healthcare Conference|
|SEATTLE--(BUSINESS WIRE)--Aug. 12, 2016--
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed
to discovering, developing and commercializing both small-molecule and
protein therapeutics for large-market as well as orphan indications
targeting inflammation, coagulopathies and disorders of the central
nervous system, today announced that Gregory A. Demopulos, M.D.,
chairman and chief executive officer, will present at the 2016 Wedbush
... || |
|08/11/16||Omeros Announces Pricing of Public Offering of Common Stock|
|SEATTLE, Aug. 11, 2016 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) announced today the pricing of a $40 million underwritten public offering of its common stock at a price to the public of $11.50 per share, before deducting underwriting discounts and commission and other estimated offering expenses. The offering is expected to close on or about August 16, 2016, subject to the satisfaction of customary closing conditions.
Cantor Fitzgerald & Co. is acting as the sole underwriter for ... || |
|08/10/16||Omeros’ Lead MASP-3 Inhibitor OMS906 Demonstrates Efficacy in Paroxysmal Nocturnal Hemoglobinuria Model|
|-- Shows Substantial Advantage over C5 Inhibitor --
SEATTLE--(BUSINESS WIRE)--Aug. 10, 2016--
Omeros Corporation (NASDAQ: OMER) today announced results from its
OMS906 complement program. OMS906 is Omeros’ lead antibody targeting
mannan-binding lectin-associated serine protease-3 (MASP-3). In a
well-established animal model associated with paroxysmal nocturnal
hemoglobinuria (PNH), OMS906 significantly improved the survival of red
blood cells ... || |
|08/10/16||Omeros Announces Public Offering of Common Stock|
|SEATTLE, Aug. 10, 2016 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced an agreement to sell $40 million of shares of its common stock to Cantor Fitzgerald & Co., as the sole underwriter, in a registered underwritten public offering.
Omeros intends to use the net proceeds of the offering for general corporate purposes, including funding research and development expenses for its clinical OMS721 program and clinical trials, pre-clinical studies, manufacturing development and o... || |
|There are currently no events scheduled.|
Receive E-mail Alerts|
|Sign up to receive e-mail alerts whenever Omeros Corporation posts new information to the site. Just enter your e-mail address and click Submit.|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.